DOCSLIB.ORG

Annual Report 2006-07

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report 2006-07 Annual Report 2006-07 Board of Directors (As on 24th July, 2007) R & D Centers Promter-Directors • Ambala-Chandigarh Highway Mr. Soshil Kumar Jain Chairman Lalru – 140 501, Punjab, India Mr. Ravinder Jain Managing Director Mr. Rajesh Jain Joint Managing Director • B-1/E-12, Mohan Co-operative Indl. Estate Mr. Sandeep Jain Joint Managing Director Mathura Road, New Delhi – 110 044, India Mr. Sumit Jain Director - Operations & Projects • A-224, Okhla Indl. Area, Phase – I Non-Executive Directors New Delhi – 110 020, India Mr. R.L. Narasimhan Director Mr. N.N. Khamitkar Director • Plot No.E-4, Phase II, Indl. Area Mr. Sunil Kapoor Director Mohali – 160 055, Punjab, India Mr. M.L. Kalra Director Mr. Gurmeet Singh Director • Plot No.Gen/73/3, T.T.C. Indl. Mr. K.M. Lal Director Estate, Mahape, Navi Mumbai – 400 710, India Dr. A.N. Saksena Director Statutory Auditors Company Secretary M/s. S.R. Batliboi & Co. Mr. Vinod Goel Chartered Accountants, New Delhi Registered Office Cost Auditors • Ambala-Chandigarh Highway M/s. J.P. Gupta & Associates Lalru – 140 501, Punjab, India Cost Accountants, New Delhi Corporate, Administrative & Registrar & Transfer Agents Secretarial Office M/s. Skyline Financial Services Pvt. Ltd. • B-1 Extn./G-3, Mohan Co-operative Indl. Estate 246, Sant Nagar, 1st Floor, Main ISKCON Temple Road, Mathura Road, New Delhi – 110 044, India East of Kailash, New Delhi – 110 065 Mumbai Office Banks • 201, `Samarpan’, New Link Road, Chakala Industrial Development Bank of India Ltd. Andheri (East), Mumbai – 400 099, India Indian Overseas Bank State Bank of India Works State Bank of Mysore • Ambala-Chandigarh Highway State Bank of Travancore Lalru – 140 501, Punjab, India Union Bank of India UTI Bank Ltd. • B-1/E-12, Mohan Co-operative Indl. Estate Mathura Road, New Delhi – 110 044, India • A-241/242, Okhla Indl. Area, Phase – I New Delhi – 110 020, India • Malpur, Baddi, Tehsil Nalagarh, Dist. Solan Himachal Pradesh – 173 205, India Chairman’s Message I look back at the last three years with a sense of I am pleased with the commitment that satisfaction and pride during which we have built a Panacea Biotec has shown in all aspects of operations, strong foundation to base our future direction. financial performance and corporate governance. It is expected to maintain the highest standards of This year has been full of significant achievements for integrity, discipline and governance while providing your Company, a 3rd successive year of record earnings superior returns to shareholders. & profitability. The performance has been in line with our strategy, where we have made significant progress To achieve our highest potential and to gear ourselves in meeting our long-term objectives. for the changing scenario, we have changed our corporate identity. This exercise has helped us As we now enter into one of the most exciting rearticulate our potential and goals. The new corporate and promising phases of our growth, cognizant identity will instill a high level of aspiration for us to of changes in the global market place and the emerge as a global health management company. Our opportunities it offers, we are confident that we have core values- Innovation, Pioneer, Integrity and Humane the resources and the determination to successfully would always guide us in taking the right decisions convert our internal capabilities into business and and lead us to our Goals. A new chapter is unfolding in operational achievements. Panacea Biotec. We will continue to focus on driving productivity and Your constant support has always been a great performance across all our business segments. As we motivating factor for us. Your confidence in us enter into global markets, meeting economic, technical will augment our efforts in finding better ways to and IPR challenges, we will endeavour to increase the do things, innovate and effectively leverage our magnitude of our business and scale new heights year knowledge and expertise in healthcare management. after year. I am glad that our methodology of steering business has received positive recognition and support I wish you all a very happy, fruitful and prosperous from our customers, staff and stakeholders. year ahead. Soshil Kumar Jain Managing Director’s Message Throughout its inception, Panacea Biotec has unwavering focus on our customers’ needs, ethical indeed come of age in a great way. We have behaviour at all levels and recognition in the witnessed an inflexion point in growth in net healthcare sector as a market leader. My confidence profit and cash earnings. It is indeed a matter of is based on our people and their adherence to a great pride to watch a continuous, sustained & methodology, a culture and a work ethic that well creditable performance. serves the interest of all our stakeholders. We have earned our reputation as innovators in We are indeed passionate about healthcare and Research & Development and marketing strategies compassionate about people. for developing high quality preventive and treatment therapies for health management. Our efforts would Having attained leadership in the domestic markets, always be to bring Panacea Biotec beyond the highest we now aspire to move fast into the global markets. quality of healthcare management. Our energetic and Our new Corporate Identity would augment our talented employees would constantly endeavour to strategic move to enter the global markets, through do that. collaborations, joint ventures and acquisitions in years to come. We have always believed in collaborative approach and our collaborations are based on a firm platform of Before concluding, I would like to express my trust, transparency and mutual benefits. admiration, appreciation & affection to all and thank all my fellow directors and the company’s staff for their I would like to accentuate the Company’s goal of dedication and relentless efforts over the year. I would providing sustainable and satisfactory shareholders’ also like to acknowledge the continued support of all returns which can only be achieved through an our customers, partners and stakeholders. Ravinder Jain Performance Highlights & Growth Gross Turnover Growth in Profitability (Rs. in million) (Rs. in million) 8,398 2,299 2,091 1,468 2,833 547 406 917 249 123 92 81 1996-97 2001-02 2006-07 1996-97 2001-02 2006-07 PAT PBT EBIDTA Growing Asset Base Growth in Net Worth (Rs. in million) (Rs. in million) 5,384 5,064 1,118 840 302 184 1996-97 2001-02 2006-07 1996-97 2001-02 2006-07 Growing Investment in R & D Growth in Shareholders’ Value (Rs. in million) (Rs. / share) 1,072 81.9 567 505 29.5 23.7 14.7 88 70 68 5.4 5.3 4.2 45 25 1.8 20 1.4 1996-97 2001-02 2006-07 1996-97 2001-02 2006-07 Revenue R & D Exp. Capital R & D Exp. Total R & D Exp. EPS Cash EPS Book Value Contents Setting the Scene 2 Auditors’ Report 70 • Financial Highlights • Glowing Highlights of the year Financial Statements 72 • Our New Corporate Identity • Balance Sheet • Profit & Loss Account Management Discussion & 8 • Schedules to Balance Sheet and Analysis Report Profit & Loss Account • Industry Structure and Developments • Cash Flow Statement • Enter the great Enterprise – Panacea Biotec • Statement u/s 212 in respect of Subsidiary Companies • Business Segments • Pharmaceutical Formulations Consolidated Financial Statements 102 • Vaccines • Auditors’ Report on Consolidated • Manufacturing Facilities Financial Statements • Research & Development • Consolidated Balance Sheet • Joint Ventures, Subsidiaries, Collaborations • Consolidated Profit & Loss Account and Tie-ups • Schedules to Consolidated Balance Sheet and • Financial Performance Profit & Loss Account • Opportunities & Outlook • Consolidated Cash Flow Statement • Future Growth Drivers • Risks, Challenges & Threats Annual Report of 126 Subsidiary Companies • Corporate Social Responsibility • Radicura & Co. Limited • Best On Health Limited Directors’ Report 44 Corporate Governance Report 56 Panacea Biotec • Annual Report 2006-07 1 Setting the Scene • Panacea Biotec is the 2nd Largest Vaccine • Company’s Brands reach more than producer in India 35 countries globally • 3rd Largest Biotechnology Company in India • Played a key role in eradicating polio cases by (ABLE Survey 2006) supplying more than 4 billion doses of Oral Polio Vaccine to Govt. of India & UNICEF • One of the six companies in the World, pre-qualified by WHO for Oral Polio Vaccine • Millions of patients enjoying happy & healthy life through our well established brands in niche • One of the nine companies in the World, therapeutic areas like pain management, diabetes pre-qualified by WHO for Hepatitis B Vaccine management, organ transplant • First Indian company to develop and launch • Stupendous contribution to Shareholders’ value innovative combination vaccines viz. Ecovac4 (Hep. B + DTP), Easyfour (Hib + DTP) and Easyfive • Over 250 Scientists working in 4 state-of-the (Hep. B + DTP + Hib) in India. art R&D Centers recognised by DSIR, Ministry of Science & Technology. • Among top 50 Pharmaceutical Companies in India – ranked 47th as per ORG IMS June’07 • Production facilities complying with International Standards • 19 product patents valid in more than 60 countries world wide • A family of around 2,800 people working relentlessly in improving quality of life of billions of • 630 patent applications filed, 211 granted globally people across the globe as on 31.03.2007 • Patient education & Public awareness focused portal www.bestonhealth.com 2 Panacea Biotec • Annual Report 2006-07 Financial Highlights (Rs. in million)
Load more

Recommended publications
  • Names of Botanical Genera Inspired by Mythology
    Names of botanical genera inspired by mythology Iliana Ilieva * University of Forestry, Sofia, Bulgaria. GSC Biological and Pharmaceutical Sciences, 2021, 14(03), 008–018 Publication history: Received on 16 January 2021; revised on 15 February 2021; accepted on 17 February 2021 Article DOI: https://doi.org/10.30574/gscbps.2021.14.3.0050 Abstract The present article is a part of the project "Linguistic structure of binomial botanical denominations". It explores the denominations of botanical genera that originate from the names of different mythological characters – deities, heroes as well as some gods’ attributes. The examined names are picked based on “Conspectus of the Bulgarian vascular flora”, Sofia, 2012. The names of the plants are arranged in alphabetical order. Beside each Latin name is indicated its English common name and the family that the particular genus belongs to. The article examines the etymology of each name, adding a short account of the myth based on which the name itself is created. An index of ancient authors at the end of the article includes the writers whose works have been used to clarify the etymology of botanical genera names. Keywords: Botanical genera names; Etymology; Mythology 1. Introduction The present research is a part of the larger project "Linguistic structure of binomial botanical denominations", based on “Conspectus of the Bulgarian vascular flora”, Sofia, 2012 [1]. The article deals with the botanical genera appellations that originate from the names of different mythological figures – deities, heroes as well as some gods’ attributes. According to ICBN (International Code of Botanical Nomenclature), "The name of a genus is a noun in the nominative singular, or a word treated as such, and is written with an initial capital letter (see Art.
    [Show full text]
  • Either a Daimon, Or a Hero, Or Perhaps a God:” Mythical Residents of Subterranean Chambers
    Kernos Revue internationale et pluridisciplinaire de religion grecque antique 15 | 2002 Varia “Either a Daimon, or a Hero, or Perhaps a God:” Mythical Residents of Subterranean Chambers Yulia Ustinova Electronic version URL: http://journals.openedition.org/kernos/1385 DOI: 10.4000/kernos.1385 ISSN: 2034-7871 Publisher Centre international d'étude de la religion grecque antique Printed version Date of publication: 1 January 2002 ISSN: 0776-3824 Electronic reference Yulia Ustinova, « “Either a Daimon, or a Hero, or Perhaps a God:” Mythical Residents of Subterranean Chambers », Kernos [Online], 15 | 2002, Online since 21 April 2011, connection on 01 May 2019. URL : http://journals.openedition.org/kernos/1385 ; DOI : 10.4000/kernos.1385 Kernos Kemos 15 (2002), p. 267-288. "Either a Daimon, or a Hero, or Perhaps a God:" Mythical Residents of Subterranean Chambers In his list of seers who uttered gods' orders and messages to mortals not only when alive, but also after their death, Strabo1 mentions "...Amphiaraos, Trophonios, Orpheus, Musaios, and the god of the Getae, formerly Zalmoxis, a Pythagorean, who is in our time Dekaineos, the diviner of Byrebistas... ,,2 Aristides groups together Trophonios, Amphiaraos, Amphilochos and the Asclepiads.3 Celsus includes Zalmoxis, Mopsos, Amphilochos, Amphiaraos, and Trophonios in his register of mortals who died and were nevertheless worshiped, whieh makes Origen wonder, "whether one of these is either a daimon, or a hero, or perhaps a god, more active than mortals" (ft ècr'tt nç èv 'toîç 'tOtQU'tOlÇ Eï'tE 8atllcov Eï'tE llPcoÇ Eï'tE Kat 8E6ç, èVEPYéOv 't!Va lldÇova ft Ka'teX av8pco1tov;).4 The bewilderment of Origen 'is reasonable, given the elusiveness of these figures.
    [Show full text]
  • Honey Plays a Significant Role in the Mythology and History of Many
    Rhododendron Ponticum Rhodora! if the sages ask thee why This charm is wasted on the earth and sky, Tell them, dear, that if eyes were made for seeing, Then beauty is its own excuse for being R.W. Emerson, ‘The Rhodora’ "The Delphic priestess in historical times chewed a laurel leaf but when she was a Bee surely she must have sought her inspiration in the honeycomb." Jane Ellen Harrison, Prologemena to Greek Religion Thy Lord taught the Bee To build its cells in hills, On trees and in man’s habitations; Then to eat of all The produce of the earth . From within their bodies comes a drink of varying colors, Wherein is healing for mankind. The Holy Koran 1 Mad Honey Contents Point of View and Introduction 4 A summary of the material 5 What the Substance is 7 A History of Honey a very short history of the relationship of humans and honey A Cultural History of Toxic Honey 9 mad honey in ancient Greece Mad Honey in the New World 10 the Americas and Australasia How the substance works 11 Psychopharmacology selected outbreaks symptoms external indicators and internal registers substances neurophysiological action medical treatment How the substance was used 13 Honied Consciousness: the use of toxic honey as a consciousness altering substance ancient Greece Daphne and Delphi Apollo and Daphne Rhododendron and Laurel Appendix 1 21 Classical References (key selections from the texts) -Diodorus Siculus -Homeric Hymns -Longus -Pausanias -Pliny The Elder -Xenephon Appendix II 29 More on Mellissa Appendix lll 30 Source of the Substances Botany and Sources of Grayanotoxin 2 Appendix lV 32 Honey and Medicine Ancient and Modern Appendix V 34 The Properties of Ethelyne Appendix Vl 36 Entrances: Food, Drink and Enemas Bibliography 39 3 Mad Honey Point of View and Introduction It’s no surprise to discover that honey, and the bees that produce it, play a notable role in mythology and religion throughout the world.
    [Show full text]
  • Trends in Vaccine Development
    ADVERTISEMENT FEATURE NATUREJOBS SPOTLIGHT ON VACCINES Trends in vaccine development How are public-private partnerships, low-cost manufacturers and new technology afecting the vaccine field? “The vaccine field BILL GATES is a handy person to grow over the next few years. the virus was identifed in 1984, to have in your corner, which In the United States, demand researchers were optimistic they is going to enlarge bodes well for those committed to will increase by around 7 percent could formulate a vaccine quickly. vaccine research. In January 2010 annually until 2015, according to a As HIV proved resilient, hopes for substantially beyond the philanthropist called for a 2011 report published by industry a fast response faded and by the SPOTLIGHT ON IMMUNOLOGY / VACCINES ON IMMUNOLOGY SPOTLIGHT “decade of vaccines” and pledged analysts Freedonia. “It’s probably early 1990s several research groups the traditional US$10 billion for vaccine research the best growth area right now in and companies had abandoned and development (R&D) and infectious disease,” says Steve Projan, the search for a vaccine. preventive vaccine.” distribution. Te Bill & Melinda senior vice president of R&D in It became clear that a new Gates Foundation funding will the innovative medicines unit at model of vaccine development was Rafi Ahmed, Emory Vaccine Center boost an already burgeoning feld. vaccine manufacturer MedImmune. needed, one that could bridge the Although vaccines comprise Te industry is being shaped by gap between the public and private a small portion of the global increased collaboration between the sectors and focus on the developing pharmaceutical market — 2 percent public and private sectors, the rise world.
    [Show full text]
  • North Sails Superyacht Clients
    NORTH SAILS SUPERYACHT CLIENTS We have been proud to work with and deliver sails for the following projects, which either already are sailing or will be launched in the year to come. If you know any of the crews of these yachts please do not hesitate to contact them to see how they feel about the sails and service they have received from us. Adela Dykstra 55m Schooner Pendennis Meteor Dykstra 50m Schooner Huisman Adele Hoek 55m Ketch Vitters Mia Cara Dubois 39m Sloop Fitzroy Anatta Dubois 66m Sloop Vitters Missy Mckeon 33m Sloop Vitters Anemoi Dubois 37m Sloop Fitzroy My Song Baltic 40m Sloop Baltic Anne Hoek 53m Sloop Vitters Mystere Tripp 43m Sloop Vitters Antares Dixon 40m Ketch Huisman Nariida Wally/Brenta 32m Ketch Wally Aquijo Tripp 85m Ketch Vitters / Oceanco Ngoni Dubois 58m Sloop Huisman Badis Briand 70m Ketch Perini Navi Nikata Nauta 35m Sloop Baltic Barong D Wally/ Frers 33m Sloop Wally Nilaya Nauta 34m Sloop Baltic Bayesian Holland 56m Sloop Perini Navi Ningaloo Dubois 45m Sloop Vitters Bella Regazza Dubois 43m Sloop Vitters Nirvana Dubois 53m Ketch Vitters Better Place Tripp/Wally 50m Sloop Wally Odin IV Frers 35m Sloop Nautor's Swan Bristolian Briand 36m Sloop CNB Panacea Frers 28m Sloop Nautor's Swan Canovo 2 Farr 42m Sloop Baltic Panthalassa Holland 56m Ketch Perini Navi Catalina Dubois 44m Ketch Vitters Path 2 J/V 34m Sloop Baltic Chimera Ted Fontaine 31m Sloop Alloy Yachts Pink Gin J/V 53m Sloop Baltic Dahlak Briand 38m Sloop Perini Navi Piropo Holland 56m Ketch Perini Navi Danneskjold Dixon 30.5m Sloop Southern Ocean
    [Show full text]
  • The Plague of Athens and the Cult of Asclepius: a Case Study of Collective Behavior and a Social Movement
    Sociology and Anthropology 4(12): 1048-1053, 2016 http://www.hrpub.org DOI: 10.13189/sa.2016.041203 The Plague of Athens and the Cult of Asclepius: A Case Study of Collective Behavior and a Social Movement Harry Perlstadt Department of Sociology, Michigan State University, East Lansing, MI 48824, United States Copyright©2016 by authors, all rights reserved. Authors agree that this article remains permanently open access under the terms of the Creative Commons Attribution License 4.0 International License Abstract During the Peloponnesian War between in the port city of Piraeus. This marks the beginning of a new Athens and Sparta, several waves of a plague killed an belief system that dealt with the failure to combat the plague. estimated one-third of the civilian Athenian population and Asclepius whose name means “to cut open,” was cut from one-fourth of its army. Thucydides account of the plague his dead mother’s womb by his father Apollo. He was (430-426 BCE) and the subsequent rise of the cult of raised by the centaur Chiron who taught him the healing arts. Asclepius can be examined as perhaps the earliest case study His sons included Machaon and Podalirius, who served as of collective behavior and a social movement. In his account surgeons and physicians during the Trojan War and among of the plague, Thucydides reveals a sociological imagination his daughters were Hygieia (health and sanitation) and and concepts including anomie and escalating stages of Panacea (cure all). The cult of Asclepius was established collective behavior. Social movements often arise in times of towards end of the 6th century at Epidaurus, located in the sudden changes and social unrest, becoming a source of Peloponnesus across the Saronic Gulf from Athens.
    [Show full text]
  • Welcome NOTE President
    2015 welcome NOTE from the president EXECUTIVE COMMITEE MEMBERS Mr. Mahendra Suhardono President Bio Farma, Indonesia Mr. Rajender Kumar Suri Dr. Akira Homma Vice President Treasurer Panacea Biotech Limited, India Bio-Manguinhos (Fiocruz),Brazil Mr. Rayasam Prasad Ms. Meng Li Mr. Patrick Tippoo Biological E. Limited, India China National Biotec Group Co.Ltd., China The Biovac Institute, South Africa Mr. Juliman Dr. Steven Gao Mr. Adar Poonawalla GAVI Board Alternate Xiamen Innovax Biotech Co. Ltd., China GAVI Board Representative Bio Farma, Indonesia Serum Institute of India Ltd., India Member Organizations’ Geographical Presence Argentina Bangladesh Brazil Cuba Egypt India Indonesia IR of Iran Mexico P.R. China Republic of Korea Saudi Arabia South Africa Taiwan Thailand Vietnam Name of the company : Arab Company for Pharmaceutical Products (Arabio) Head of Institution : Dr. Majed Saeed Bahatheq (Arabio CEO) Established : Arabio is a limited liability company established in 2005 Location : Saudi Arabia Overview of the company Arabio is a biopharmaceutical company specialized in human vaccines, and other biopharmaceuticals. It is the first biopharmaceutical company in the Gulf Cooperation Council (GCC). The size and scope of activities intended to be made in Arabio would make Arabio the first biological company of its kind in the Middle East. Arabio aims to bring to the markets of the Middle East, North Africa, and high quality products that comply with the international quality standards. Arabio has production lines of pre-filled syringes, liquid vials and lyophilized vials from the best global machines suppliers to make high quality products and meet cGMP & international standards. Description of ARABIO capabilities – Biological sterile manufacturing – PFS and vial filling – PFS and vial blister packaging Arabio Partners: 1.
    [Show full text]
  • PDF: 300 Pages, 5.2 MB
    The Bay Area Council Economic Institute wishes to thank the sponsors of this report, whose support was critical to its production: The Economic Institute also wishes to acknowledge the valuable project support provided in India by: The Bay Area Council Economic Institute wishes to thank the sponsors of this report, whose support was critical to its production: The Economic Institute also wishes to acknowledge the valuable project support provided in India by: Global Reach Emerging Ties Between the San Francisco Bay Area and India A Bay Area Council Economic Institute Report by R. Sean Randolph President & CEO Bay Area Council Economic Institute and Niels Erich Global Business/Transportation Consulting November 2009 Bay Area Council Economic Institute 201 California Street, Suite 1450 San Francisco, CA 94111 (415) 981-7117 (415) 981-6408 Fax [email protected] www.bayareaeconomy.org Rangoli Designs Note The geometric drawings used in the pages of this report, as decorations at the beginnings of paragraphs and repeated in side panels, are grayscale examples of rangoli, an Indian folk art. Traditional rangoli designs are often created on the ground in front of the entrances to homes, using finely ground powders in vivid colors. This ancient art form is believed to have originated from the Indian state of Maharashtra, and it is known by different names, such as kolam or aripana, in other states. Rangoli de- signs are considered to be symbols of good luck and welcome, and are created, usually by women, for special occasions such as festivals (espe- cially Diwali), marriages, and birth ceremonies. Cover Note The cover photo collage depicts the view through a “doorway” defined by the section of a carved doorframe from a Hindu temple that appears on the left.
    [Show full text]
  • Panacea Biotec Receives $24.32M Award from UN Agencies
    Panacea Biotec receives $24.32M award from UN Agencies 23 December 2019 | News | By Manbeena Chawla Easyfive-TT (DTwP-HepB-Hib) was introduced by Panacea Biotec as world’s first fully liquid wP-based pentavalent vaccine in Indian market in 2005. New Delhi based biotechnology company Panacea Biotec has received Awards worth USD 24.32 Million (Over Rs.170 crores) from U.N. Agencies (UNICEF and PAHO) for supply of its Easyfive-TT, a fully liquid WHO prequalified Pentavalent Vaccine. UNICEF award is for year 2020 and award of PAHO is for three (3) years i.e. 2020-2022. Pediatric vaccination plays an important role to achieve Sustainable Development Goals set by the United Nations, in particular the target to reduce under-five mortality rate to less than 25 per 1000 live births. Pentavalent vaccine protects children against five deadly diseases; Diphtheria, Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b – becoming the foundation of paediatric immunization programs across the world. Easyfive-TT (DTwP-HepB-Hib) was introduced by Panacea Biotec as world’s first fully liquid wP-based pentavalent vaccine in Indian market in 2005. With WHO prequalification in 2008, over 100 million doses have been supplied to more than 50 countries globally. Easyfive-TT is ready for use without further preparation by healthcare workers in the field, which offers major healthcare advantages in countries with challenging infrastructure and hygiene problems. Panacea Biotec has contributed significantly for Children’s Health and has partnered with WHO, UNICEF & PAHO in their efforts to maximize coverage of vaccines under the Expanded Program on Immunization (EPI) in developing countries.
    [Show full text]
  • REGISTER of SPONSORS (Tiers 2 & 5 and Sub Tiers Only)
    REGISTER OF SPONSORS (Tiers 2 & 5 and Sub Tiers Only) DATE: 08-February-2019 Register of Sponsors Licensed Under the Points-based System This is a list of organisations licensed to sponsor migrants under Tiers 2 & 5 of the Points-Based System. It shows the organisation's name (in alphabetical order), the sub tier(s) they are licensed for, and their rating against each sub tier. A sponsor may be licensed under more than one tier, and may have different ratings for each tier. No. of Sponsors on Register Licensed under Tiers 2 and 5: 29,567 Organisation Name Town/City County Tier & Rating Sub Tier ?What If! Ltd London Tier 2 (A rating) Tier 2 General Tier 2 (A rating) Intra Company Transfers (ICT) @ Home Accommodation Services Ltd London Tier 2 (A rating) Tier 2 General Tier 5 (A rating) Creative & Sporting ]performance s p a c e [ Folkestone Kent Tier 5 (A rating) Creative & Sporting 0-two Maintenance London Tier 2 (A rating) Tier 2 General 1 minus 1 Limited Farnham Surrey Tier 2 (A rating) Tier 2 General 1 Stop Halal Limited Eye Suffolk Tier 2 (A rating) Tier 2 General 1 Stop Print Ltd Ilford Tier 2 (A rating) Tier 2 General 1 Tech LTD London Tier 2 (A rating) Tier 2 General 10 Europe Limited Edinburgh Tier 2 (A rating) Tier 2 General Tier 2 (A rating) Intra Company Transfers (ICT) 10 GROUP LTD T/A THE 10 GROUP LONDON Tier 2 (A rating) Tier 2 General Page 1 of 1951 Organisation Name Town/City County Tier & Rating Sub Tier 100 SHAPES LTD LONDON Tier 2 (A rating) Tier 2 General 1000heads Ltd London Tier 2 (A rating) Tier 2 General 1000mercis
    [Show full text]
  • Manufacturing Permission of Human Vaccines Year 2021
    Manufacturing Permission of Human Vaccines Year 2021 S. No. Name of Firm Name of Molecule Indication Date Approved 1 M/s Serum Institute ChAdOx1 nCoV-19 For Restricted use in emergency Permission No. of India Pvt. Ltd. Corona Virus Vaccine situation: MF/BIO/21/000001 dated 212/2, Off. Soli (Recombinant) For active immunization of 03.01.2021 Poonawalla Road, individuals of ≥18 years old for the Hadapsar Pune, prevention of corona virus disease Maharashtra, India. (COVID-19) when administered in two doses schedule. The second dose should be administered between 4 to 6 weeks after the first dose. However, there is data available for administration of the second dose up to 12 weeks after the first dose from the overseas studies. 2 M/s Bharat Biotech Whole Virion Inactivated For Restricted use in emergency Permission No. International Corona Virus Vaccine, situation in clinical trial mode: MF/BIO/21/000002 dated Limited, Sy. No. [BBV152] For active immunization against 03.01.2021 230, 231 & 235, Corona Virus Disease (COVID-19) Genome Valley, for age ≥12 years when Shameerpet administered in two doses interval Mandal, Medchal- of day 0 & day 28. Malkajgiri District, Telangana-500078, India. Manufacturing Permission of Human Vaccines Year 2020 S. No. Name of Firm Name of Molecule Indication Date Approved 1 M/s Biological E. Typhoid Vi Conjugate For active immunization against MF/BIO/20/000001 dated Limited, Plot No. 1, Vaccine, IP infection caused by Salmonella 28.01.2020 Phase II, Biotech typhi in infants, children, Park, Kolthur adolescents and adults aged ≥ 6 Village, Shameerpet months to ≤ 45 years.
    [Show full text]
  • Annual Report 17-18 Initial Pages for Web.Cdr
    Contents Safe Harbour Statement Corporate Information 01 This report contains forward-looking statements, which may be identied by their use of words like Tribute to Late Shri Ravinder Jain 02 ‘plans’, ‘expects’, ‘will’, ‘anticipates’, ‘believes’, Vision, Mission & Values 03 ‘intends’, ‘projects’, ‘estimates’, or other words of similar meaning. All statements that address Chairman's Message 04 expectations or projections about the future, Panacea Biotec at a Glance 06 including but not limited to statements about Company’s future growth drivers, product Financial Highlights 07 development, market position and expenditures Core Strengths 08 are forward looking statements. Forward looking statements are based on certain assumptions and Management Discussion & Analysis 10 expectations for future events. The Company may Directors' Report 25 not guarantee that these assumptions and expectations are accurate and will be realised. The Corporate Governance Report 49 Company’s actual results, performance or Auditors' Report on Standalone achievements could thus differ materially from Financial Statements 66 those projected in any forward-looking Standalone Financial Statements 72 s t ate m e nt s. Th e Co m p a ny a s s u m e s n o responsibility to publicly amend, modify, revise Auditors' Report on Consolidated any forward-looking statements, on the basis of Financial Statements 106 any subsequent developments, information and Consolidated Financial Statements 110 events. Mr. Soshil Kumar Jain, Chairman (Sitting) along with his colleagues on the Board and other officials (from left) Mr. Mahipat Singh, Mr. Vinod Goel, Mr. N. N. Khamitkar, Mr. O. P. Kelkar, Mr. Mukul Gupta, Mr. K. M. Lal, Dr.
    [Show full text]